Discovery and extensive in vitro evaluations of NK-HDAC-1: A chiral histone deacetylase inhibitor as a promising lead

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3066-3075

  Hou, Jingli ^a   Li, Zhonghua ^a   Fang, Qinghong ^a   Feng, Congran ^a   Zhang, Hanwen ^a   Guo, Weikang ^a   Wang, Huihui ^a   Gu, Guoxian ^a   Tian, Yinping ^a   Liu, Pi ^a   Liu, Ruihua ^a   Lin, Jianping ^a   Shi, Yi Kang ^b   Yin, Zheng ^a   Shen, Jie ^a   Wang, Peng George ^a  

^a NANKAI UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 [1 (BENZO[D]OXAZOL 2 YL) 2 METHYL PROPYL] 1H 1,2,3 TRIAZOL 4 YL]N HYDROXYACRYLAMIDE; CARBENE; CYTOCHROME P450 3A4; HISTONE DEACETYLASE INHIBITOR; NSC 746457; ORGANOLEAD COMPOUND; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CELL ASSAY; CHIRALITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; ENZYMATIC ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZOLES; CACO-2 CELLS; CELL LINE, TUMOR; CLICK CHEMISTRY; CYTOCHROME P-450 CYP3A; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; PERMEABILITY; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84859789575     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201496g     Document Type: Article

References (29)

1. Shen, J.; Woodward, R.; Kedenburg, J. P.; Liu, X. W.; Chen, M.; Fang, L. Y.; Sun; D. X.; Wang. P. G. J. Med. Chem. 2008, 51, 7417 - 7427
2. Shen, J.; Woodward, R.; Kedenburg, J. P.; Liu, X. W.; Chen, M.; Fang, L. Y.; Sun, D. X.; Wang., P. G. J. Med. Chem. 2008, 51, 7417-7427
3. Kouzarides, T. Chromatin modifications and their function Cell 2007, 128, 693-705
4. Bernstein, B. E.; Meissner, A.; Lander, E. S. The mammalian epigenome Cell 2007, 128, 669-681
5. Li, E. Chromatin modification and epigenetic reprogramming in mammalian development Nat. Rev. Genet. 2002, 3, 662-673
6. Trojer, P.; Reinberg, D. Histone lysine demethylases and their impact on epigenetics Cell 2006, 125, 213-217
7. Yang, X. J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men Nat. Rev. Mol. Cell Biol. 2008, 9, 206-218
8. Wolffe, A. P. Histone deacetylase: a regulator of transcription Science 1996, 272, 371-372
9. Wu, J; Grunstein, M. 25 years after the nucleosome model: chromatin modification Trends Biochem. Sci. 2000, 25, 619-623
10. Marks, P. A.; Dokmanovic, M. Histone deacetylase inhibitors: discovery and development as anticancer agents Expert Opin. Invest. Drugs 2005, 14, 1497-1511
11. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer. 2006, 6, 38-51
12. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401, 188-193
13. Cho, Y. S.; Whitehead, L.; Chen, C. H.; Jiang, L.; Francotte, E.; Richert, P.; Wagner, T.; Traebert, M.; Lu, Q.; Cao, X.; Dumotier, B.; Fejzo, J.; Rajan, S.; Wang, P.; Yan-Neale, Y.; Shao, W.; Atadja, P..; Shultz, M. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824) J. Med. Chem. 2010, 53, 2952-2963
14. Lu, Q.; Wang, D.-S.; Chen, C.-S.; Hu, Y.-D.; Chen, C.-S. Structure-based optimization of phenylbutyrate-derived histone. deacetylase inhibitors J. Med. Chem. 2005, 48, 5530-5535
15. Hou, J.; Feng, C.; Li, Z.; Fang, Q.; Wang, H.; Gu, G.; Shi, Y.; Liu, P.; Xu, F.; Zheng, Y.; Shen, J.; Wang, P. Structure-based optimization of click-based histone deacetylase inhibitors Eur. J. Med. Chem. 2011, 46, 3190-3200
16. Yoshida, M.; Hoshikawa, Y.; Koseki, K.; Mori, K.; Beppu, T.. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells J. Antibiot. 1990, 43 (9) 1101-6
17. Jagr, M.; Mraz, J.; Linhart, I.; Stransky, V.; Pospisil, M. Synthesis and characterization of styrene oxide adducts with cysteine, histidine, and lysine in human globin Chem. Res. Toxicol. 2007, 20, 1442-52
18. Coon, M. J.; Vaz, A. D. N.; McGinnity, D. F. peng, H.M. Multiple activated oxygen species in P450 catalysis: contributions to specificity in drug metabolism Drug Metab. Dispos. 1998, 26, 1190-1193
19. Tamás Kálai, J. J.; Erzsébet, O.; Kálmán, H. Synth. Commun. 2003, 33, 1433-1442
20. Jernigan, F. E.; Sieracki, N. A.; Taylor, M. T.; Jenkins, A. S.; Engel, S. E.; Rowe, B. W.; Jové, F. A.; Yap, G. P. A.; Papish, E. T.; Ferrence, G.M.. Sterically bulky tris(triazolyl)borate ligands as water-soluble analogues of tris(pyrazolyl)borate Inorg. Chem. 2007, 46, 360-362
21. Bloom, A.; Day, A. R. The Preparation of 2-Alkylaminobenzimidazoles J. Org. Chem. 1939, 4, 14-19
22. Jaguar, version 7.8; Schrodinger, LLC: New York, 2011.
23. Cronin, C. N.; Hilgers, M. T.; Knuth, M. W.; Navre, M. E.; Sang, C.; Skene, R. J.; Tari, L. W.; Wilson, K. P.; Witemer, D.; Zou, H. Crystallization of Histone Deacetylase 2. US 7507552 B1, 2009; pp 197
24. FDA approval and new drug application (NDA) documents for Zolinza (SAHA, vorinostat). http://www.accessdata.fda.gov/drugsatfda-docs/nda/2006/021991s000- ZolinzaTOC.cfm
25. Guo, W.; Lu, Y.; Li., R..; Li, Y.; Li, Z.; Hou, J.; Liu, R.; Yuan, S.; Shen, J.; Wang, P. G. Preclinical evaluations of NK-HDAC-1 as a new anti-cancer drug candidate. The results will be published in the future
26. Wang, H.; Lim, Z.-Y.; Zhou, Y.; Ng, M.; Lu, T.; Lee, K.; Sangthongpitag, K.; Goh, K. C.; Wang, X.; Wu, X.; Khng, H. H.; Goh, S. K.; Ong, W. C.; Bonday, Z.; Sun, E. T. Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: synthesis, SAR, and in vivo antitumor activity Bioorg. Med. Chem. Lett. 2010, 20, 3314-3321
27. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a lamarckian genetic algorithm and and empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662
28. Sanner, M. F. Python: A programming language for software integration and development J. Mol. Graphics Modell. 1999, 17, 57-61
29. Cai, Y. Y.; Yap, C. W.; Wang, Z.; Ho, P. C.; Chan, S. Y.; Ng, K. Y.; Ge, Z. G.; Lin, H. S. Solubilization of vorinostat by cyclodextrins J. Clin. Pharm. Ther. 2010, 35 (5) 521-526